Previous research with a [177Lu]Lu-labelled HER2 antibody, trastuzumab, and a nanobody (2Rs15d), demonstrated successful targeting for in vivo imaging and tumour reduction using [177Lu]Lu-DPTA-2Rs15d in HER2-tumour-bearing mice [154]. Here, ERBB2 is linked to neoplasm.